Claims
- 1. A unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid.
- 2. The formulation according to claim 1, which comprises at least 0.25 mg of prednisolone or said equivalent.
- 3. The formulation according to claim 2, which comprises 0.5 to 2 mg of prednisolone or said equivalent.
- 4. The formulation according to claim 3, which comprises 1 to 1.25 mg of prednisolone or said equivalent.
- 5. The formulation according to claim 1, adapted to release at least 90% by weight of prednisolone or said equivalent 2 to 8 hours after administration.
- 6. The formulation according to claim 1, wherein said corticosteroid is a glucocorticoid.
- 7. The formulation according to claim 1, wherein said corticosteroid is selected from the group consisting of prednisone, budesonide, methylprednisolone, fluticasone, betamethasone, and deflazacort.
- 8. The formulation according to claim 7, wherein said corticosteroid is prednisone.
- 9. A method for the treatment of a patient suffering from a condition selected from the group consisting of asthma, inflammatory bowel disease, psoriasis, psoriatic arthritis, polymyalgia rheumatica, chronic obstructive pulmonary disease, and rheumatoid arthritis and other polyarthropathies, which comprises administering to the patient a unit dosage formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid.
- 10. The method according to claim 9, wherein the formulation comprises at least 0.25 mg of prednisolone or said equivalent.
- 11. The method according to claim 10, wherein the formulation comprises 0.5 to 2 mg of the prednisolone or said equivalent.
- 12. The method according to claim 11, wherein the formulation comprises 1 to 1.25 mg of the prednisolone or said equivalent.
- 13. The method according to claim 9, wherein the formulation is adapted to release at least 90% by weight of the prednisolone or said equivalent 2 to 8 hours after administration.
- 14. The method according to claim 9, wherein said corticosteroid is a glucocorticoid.
- 15. The method according to claim 9, wherein said corticosteroid is selected from the group consisting of prednisone, budesonide, methylprednisolone, flutacasone, betamethasone, and deflazacort.
- 16. The method according to claim 15, wherein said corticosteroid is prednisone.
- 17. The method according to claim 8, wherein said corticosteroid is administered between midnight and 6 a.m.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9905898 |
Mar 1999 |
GB |
|
0023220 |
Sep 2000 |
GB |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of International Application PCT/GB01/04181, with an international filing date of Sep. 19, 2001, published in English under PCT Article 21(2), and is a continuation-in-part of U.S. application Ser. No. 09/936,586, filed Sep. 13, 2001 now U.S. Pat. No. 6,488,960.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5792476 |
Hällgren |
Aug 1998 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9508323 |
Mar 1995 |
WO |
Non-Patent Literature Citations (3)
Entry |
Rote Liste, 1998, 31 037 Decortin H 1mg. |
Buckley, L.M. et al., “Effects of Low Dose Corticosteroids on the Bone Mineral Density of Patients with Rheumatoid Arthritis” The Journal of Rheumatology, 1995, pp. 1055-1059, vol. 22, No. 6. |
Cash, J.M. et al. “Pituitary-Adrenal Axis Responsiveness to Ovine Corticotropin Releasing Hormone in Patients with Rheumatoid Arthritis Treated with Low Dose Prednisone” The Journal of Rheumatology, 1992, pp. 1692-1696, vol. 19, No. 11. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/GB01/04181 |
Sep 2001 |
US |
Child |
10/263044 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/936586 |
Sep 2001 |
US |
Child |
PCT/GB01/04181 |
|
US |